When you’re a brilliant mathematician like the Baltimore Ravens’ John Urschel, a football playbook is only so challenging. So the 6-foot-3, 305-pound offensive lineman looks for mathematics in everyday life for mental stimulation, and he’s asking you to do the same. Get in the game by snapping photos of how and where you use math at school, at home, on the practice field — anywhere and everywhere – for a chance to win a $500 Amazon gift card and a video conference for your class with the professional athlete.
Kicking off August 19, in coordination with World Photo Day (#WorldPhotoDay), and running through September 17, you can show John Urschel how you use math for the win in everyday life on Twitter or Instagram using the hashtags #MathFTW and #TIContest to be entered to win. And, get creative! The gifted mathematician is seeing a lot of math these days as he pursues his Ph.D. in Applied Mathematics at Massachusetts Institute of Technology (MIT). Urschel, who holds a 4.0 Grade Point Average, is all the proof students need to see they can be good at academics while pursuing other passions – from athletics to the arts.
To view the multimedia release go to:
http://www.multivu.com/players/English/7746253-texas-instruments-math-for-the-win-contest/
Regional winners of the Rotten Sneaker Contest® gathered at Ripley’s Believe It Or Not! Times Square for the 2016 national competition. Six contestants from across the country, ages seven to thirteen, went head-to head in New York City today to show off their foul smelling sneakers for a chance to win the national title. But only one pair of sneakers could be crowned the winner and they belonged to 12 year old, Mason Young-Hiss, from Berthoud, CO.
The Odor-Eaters Rotten Sneaker Contest is the ultimate test that shows how offensive kids’ sneakers can get when they are playing outdoors, splashing through puddles, slogging through mud and more. The contest has a long history (over 40 years) and kids from across the country look forward to this annual event in their hometown. Participants take pride in mucking up their shoes to stand out from their competitors to ultimately win over the judges. Sneakers are judged on the interior and exterior conditions of the shoe, and most importantly odor, by a professional panel that includes NASA “Master Sniffer” George Aldrich, Chemical Specialist for NASA space missions, and Rachel Herz, Ph.D., an expert and author on the psychology of smell. Additionally, Brittany Every, Marketing Manager of Ripley’s Believe Or Not! Times Square joined the expert judges this year. Brittany is accustomed to seeing the unexpected and unusual at Ripley’s so she was up for the task.
To view the multimedia release go to:
http://www.multivu.com/players/English/7720051-odor-eaters-rotten-sneaker-contest/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Testfahrt mit dem neuen Golf GTI zum Wörthersee dem Mekka der GTI-Fahrer. Nahezu 1,9 Millionen Golf GTI wurden bislang im Volkswagen Werk Wolfsburg hergestellt und weltweit verkauft. Damals, 1976, als der GTI erfunden wurde, ahnte diesen Erfolg niemand. 5.000 Exemplare waren geplant, von einem Auto, das heute das erfolgreichste seiner Art auf der Welt ist. Ein Phänomen. Präziser als jeder Kompaktwagen zuvor definierte der erste Golf GTI vor 37 Jahren ein Ur-Maß der Dynamik, zudem machte der erschwingliche Volkswagen die automobile Sportlichkeit für mehr Menschen denn je erreichbar. Jetzt startet eine neue, die siebte GTI-Generation durch.
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
